Acta Scientific Medical Sciences (ISSN: 2582-0931)

Research Article Volume 4 Issue 1

Pharmacological Effect of Krameria cytisoides on Trypanosoma cruzi in vitro and in vivo Krameria cytisoides on Trypanosoma cruzi

Jiménez-Cardoso E1*, Soto-Quintanar L1, Nogueda-Torres B2 and Pérez-Gutiérrez MS3

1Hospital Infantil De México Federico Gómez, Laboratorio De Investigación En Parasitología, Ciudad De México

2Laboratorio De Helmintos, Departamento De Parasitología, ENCB-IPN

3Universidad Autónoma Metropolitana, Unidad-Xochimilco

*Corresponding Author: Jiménez-Cardoso E, Hospital Infantil De México Federico Gómez, Laboratorio De Investigación En Parasitología, Ciudad De México.

Received: December 05, 2019; Published: December 24, 2019



Objective: The know the pharmacological effect of Krameria cytisoides extract in vitro and in vivo, as well as the cytotoxicity of this compound, determined.

Material and Methods: For in vitro determination, concentrations of 40, 80 and 160 mg/kg of K. cytisoides were used. Cytotoxicity was assessed with VERO cells using concentrations between 10 and 160 µg/L. The pharmacological effect in vivo was investigated with five groups males per groups 3 of Balb/c mice. All mice were inoculated with 1x103/ µL trypomastigotes. Three groups were injected with 40, 80 or 160 mg/mL. The fourth group was treated with 100 mg/kg of the benznidazole reference drug, and no treatment was given to the fifth group.

Results: The results demonstrated that the LD50 was 69 µg/mL, with an LC50 cytotoxicity of 160 µg/mL; thus, no toxic effect was observed. Regarding the in vivo results, 61% and 74% flagellates death was observed at the highest concentration of K. cytisoides, and the reference drug benznidazole, respectively.

Discussion and Conclusions: According to the results, the low toxicity and lethality of K. cytisoides compared to benznidazole suggests that the former could be used as a drug of choice for Chagas disease.

Keywords: Krameria Cytisoides; T. Cruzi; Epimastigotes; Trypomastigotes



  1. Pan American Health Organization. Estimación cuantitativa de la enfermedad de Chagas en las Américas. Montevideo, Uruguay: Organización Panamericana de la Salud (2006).
  2. Rassi A Jr., et al. “Chagas disease”. Lancet 375 (2010):1388-1402.
  3. Sosa-Estani S., et al. “Therapy of chagas disease: implications for levels of prevention”. Journal of Tropical Medicine (2012): 292138.
  4. Apt WB and Zulantay AI. “Estado actual en el tratamiento de la enfermedad de Chagas”. Revista Médica de Chile 139 (2011): 247-257.
  5. Maya JD., et al. “Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host”. Comparative Biochemistry and Physiology 146 (2007): 601-620.
  6. Martínez M. “Las plantas medicinales de México”. Ediciones Botas México, DF (1995): 90.
  7. Chiari E., et al. “Hemocultures for the parasitological diagnosis of human chronic chagas’ disease”. Revista da Sociedade Brasileira de Medicina Tropical 22 (1989):19-28.
  8. Pérez-Gutièrrez S., et al. “Kramecyne a new anti-inflammatory compound isolated from Krameria cytisoides”. Molecules2 (2012): 2049-2057.
  9. Jimenez-Coello M., et al. “Antitrypanosomal activity of Senna villosa in infected BALB/c mice with Trypanosoma cruzi during the sub-acute phase of infection”. African Journal of Traditional, Complementary and Alternative Medicines 8 (2011): 164-169.
  10. Grael CF., et al. “A study of the trypanocidal and analgesic properties from Lychnophora granmongolense (Duarte) Semir and Leitão Filho”. Phytotherapy Research 14 (2000): 203-206.
  11. Polanco-Hernández G., et al. “In vitro and in vivo trypanocidal activity of native plants from the Yucatan Peninsula”. Parasitology Research 1 (2012): 31-35.
  12. The Angiosperm Phylogeny Group III ("APG III", en orden alfabético: Brigitta Bremer., et al. “An update of the Angiosperm Phylogeny Group classification for the orders and families of flowering plants: APG III”. Botanical Journal of the Linnean Society 161 (2009): 105-121.
  13. Organización Panamericana de la Salud, Organización Mundial de la Salud. Estimación cuantitativa de la Enfermedad de Chagas en las Américas. OPS/HDM/CD/425-06. PAHO/WHO (2006).
  14. Wink M. “Medicinal Plants: a source of anti-parasitic secondary metabolites”. Molecules 17 (2012): 12771-12791.
  15. Díaz-Chiguer DL., et al. “In vitro and in vivo trypanocidal activity of some benzimidazole derivatives against two strains of Trypanosoma cruzi”. Acta Tropica 122 (2012): 108-112.
  16. Alviano DS., et al. “Conventional therapy and promising plant-derived compounds against trypanosomatid parasites”. Frontiers in Microbiology 3 (2000): 283.
  17. Urbina JA., et al. “In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob”. Agents and Chemotherapy 44 (2000): 2498-2502.


Citation: Jiménez-Cardoso E., et al. "Pharmacological Effect of Krameria cytisoides on Trypanosoma cruzi in vitro and in vivo Krameria cytisoides on Trypanosoma cruzi". Acta Scientific Medical Sciences 4.1 (2020): 141-145.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US